Measuring iga anti-β2-glycoprotein i and igg/iga anti-domain i antibodies adds value to current serological assays for the antiphospholipid syndrome

PLoS ONE

Volumn 11, Issue 6, 2016, Pages

  Pericleous, Charis ^a   Ferreira, Isabel ^a   Borghi, Orietta ^b   Pregnolato, Francesca ^b   McDonnell, Thomas ^a   Garza Garcia, Acely ^c   Driscoll, Paul ^c   Pierangeli, Silvia ^d   Isenberg, David ^a   Ioannou, Yiannis ^a,e   Giles, Ian ^a   Meroni, Pier Luigi ^b   Rahman, Anisur ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b ISTITUTO AUXOLOGICO ITALIANO   (Italy)

^c NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (United Kingdom)

^d UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^e GREAT ORMOND STREET HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA2 GLYCOPROTEIN 1 ANTIBODY; CARDIOLIPIN ANTIBODY; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; LUPUS ANTICOAGULANT; BETA2 GLYCOPROTEIN 1; EPITOPE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; PHOSPHOLIPID ANTIBODY;

ADULT; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC VALUE; FEMALE; HAZARD RATIO; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PREGNANCY COMPLICATION; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SYSTEMIC LUPUS ERYTHEMATOSUS; BLOOD; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOLOGY; ISOLATION AND PURIFICATION; MIDDLE AGED; PATHOLOGY; PREGNANCY; SEROLOGY; THROMBOSIS;

ADULT; ANTIBODIES, ANTICARDIOLIPIN; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; BETA 2-GLYCOPROTEIN I; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES; FEMALE; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; PREGNANCY; SEROLOGIC TESTS; THROMBOSIS;

EID: 84973661586     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0156407     Document Type: Article

References (47)

1. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006; 4:295-306. PMID: 16420554
2. Willis R, Harris EN, Pierangeli SS. Current international initiatives in antiphospholipid antibody testing. Semin Thromb Hemost. 2012; 38:360-74. doi: 10.1055/s-0032-1313564 PMID: 22576664
3. Swadzba J, Sydor WJ, Kolodziejczyk J, Musial J. Summary of the 9th meeting of the European Forum on Antiphospholipid Antibodies. Lupus. 2014; 23:395-9. doi: 10.1177/0961203314520841 PMID: 24474705
4. Andreoli L, Fredi M, Nalli C, Piantoni S, Reggia R, Dall'Ara F, et al. Clinical significance of IgA anti-cardiolipin and IgA anti-beta2glycoprotein I antibodies. Curr Rheumatol Rep. 2013; 15:343. doi: 10.1007/ s11926-013-0343-1 PMID: 23754504
5. Murthy V, Willis R, Romay-Penabad Z, Ruiz-Limon P, Martinez-Martinez LA, Jatwani S, et al. Value of isolated IgA anti-beta2 -glycoprotein I positivity in the diagnosis of the antiphospholipid syndrome. Arthritis Rheum. 2013; 65:3186-93. doi: 10.1002/art.38131 PMID: 23983008
6. Galli M, Comfurius P, Maassen C, Hemker HC, de Baets MH, van Breda-Vriesman PJ, et al. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet. 1990; 335:1544-7. PMID: 1972485
7. McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2- glycoprotein I (apolipoprotein H). Proc Natl Acad Sci U S A. 1990; 87:4120-4. PMID: 2349221
8. Giannakopoulos B, Krilis SA. The pathogenesis of the antiphospholipid syndrome. New Engl J Med. 2013; 368:1033-44. doi: 10.1056/NEJMra1112830 PMID: 23484830
9. Meroni P, Chighizola C, Rovelli F, Gerosa M. Antiphospholipid syndrome in 2014: more clinical manifestations, novel pathogenic players and emerging biomarkers. Arthritis Res Ther. 2014; 16:209-22. PMID: 25166960
10. Ioannou Y, Zhang JY, Passam FH, Rahgozar S, Qi JC, Giannakopoulos B, et al. Naturally occurring free thiols within beta 2-glycoprotein I in vivo: nitrosylation, redox modification by endothelial cells, and regulation of oxidative stress-induced cell injury. Blood. 2010; 116:1961-70. doi: 10.1182/blood-2009-04-215335 PMID: 20551379
11. de Laat B, Derksen RH, van Lummel M, Pennings MT, de Groot PG. Pathogenic anti-beta2-glycoprotein I antibodies recognize domain I of beta2-glycoprotein I only after a conformational change. Blood. 2006; 107:1916-24. PMID: 16269621
12. Agar C, van Os GM, Morgelin M, Sprenger RR, Marquart JA, Urbanus RT, et al. Beta2-glycoprotein I can exist in 2 conformations: implications for our understanding of the antiphospholipid syndrome. Blood. 2010; 116:1336-43. doi: 10.1182/blood-2009-12-260976 PMID: 20462962
13. de Laat B, de Groot PG. Autoantibodies directed against domain I of beta2-glycoprotein I. Curr Rheumatol Rep. 2011; 13:70-6. doi: 10.1007/s11926-010-0144-8 PMID: 21046294
14. Mahler M, Norman GL, Meroni PL, Khamashta M. Autoantibodies to domain 1 of beta 2 glycoprotein 1: a promising candidate biomarker for risk management in antiphospholipid syndrome. Autoimmun Rev. 2012; 12:313-7. doi: 10.1016/j.autrev.2012.05.006 PMID: 22652408
15. Andreoli L, Chighizola CB, Nalli C, Gerosa M, Borghi MO, Pregnolato F, et al. Clinical Characterization of Antiphospholipid Syndrome by Detection of IgG Antibodies Against beta2 -Glycoprotein I Domain 1 and Domain 4/5: Ratio of Anti-Domain 1 to Anti-Domain 4/5 As a Useful New Biomarker for Antiphospholipid Syndrome. Arthritis Rheumatol. 2015; 67:2196-204. doi: 10.1002/art.39187 PMID: 25939498
16. Iverson GM, Victoria EJ, Marquis DM. Anti-beta2 glycoprotein I (beta2GPI) autoantibodies recognize an epitope on the first domain of beta2GPI. Proc Natl Acad Sci U S A. 1998; 95:15542-6. PMID: 9861005
17. Reddel SW, Wang YX, Sheng YH, Krilis SA. Epitope studies with anti-beta 2-glycoprotein I antibodies from autoantibody and immunized sources. J Autoimmun. 2000; 15:91-6. PMID: 10968891
18. Iverson GM, Reddel S, Victoria EJ, Cockerill KA, Wang YX, Marti-Renom MA, et al. Use of single point mutations in domain I of beta 2-glycoprotein I to determine fine antigenic specificity of antiphospholipid autoantibodies. J Immunol. 2002; 169:7097-103. PMID: 12471146
19. de Laat B, Derksen RH, Urbanus RT, de Groot PG. IgG antibodies that recognize epitope Gly40-Arg43 in domain I of beta 2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis. Blood. 2005; 105:1540-5. PMID: 15507529
20. Ioannou Y, Pericleous C, Giles I, Latchman DS, Isenberg DA, Rahman A. Binding of antiphospholipid antibodies to discontinuous epitopes on domain I of human beta(2)-glycoprotein I: mutation studies including residues R39 to R43. Arthritis Rheum. 2007; 56:280-90. PMID: 17195232
21. de Laat B, Pengo V, Pabinger I, Musial J, Voskuyl AE, Bultink IE, et al. The association between circulating antibodies against domain I of beta2-glycoprotein I and thrombosis: an international multicenter study. J Thromb Haemost. 2009; 7:1767-73. doi: 10.1111/j.1538-7836.2009.03588.x PMID: 19694946
22. Andreoli L, Nalli C, Motta M, Norman GL, Shums Z, Encabo S, et al. Anti-beta(2)-glycoprotein I IgG antibodies from 1-year-old healthy children born to mothers with systemic autoimmune diseases preferentially target domain 4/5: might it be the reason for their 'innocent' profile? Ann Rheum Dis. 2011; 70:380-3. doi: 10.1136/ard.2010.137281 PMID: 20971718
23. Pericleous C, Ruiz-Limon P, Romay-Penabad Z, Marin AC, Garza-Garcia A, Murfitt L, et al. Proof-ofconcept study demonstrating the pathogenicity of affinity-purified IgG antibodies directed to domain I of beta2-glycoprotein I in a mouse model of anti-phospholipid antibody-induced thrombosis. Rheumatology (Oxford). 2015; 54:722-7.
24. Pericleous C, Miles J, Esposito D, Garza-Garcia A, Driscoll PC, Lambrianides A, et al. Evaluating the conformation of recombinant domain I of beta(2)-glycoprotein I and its interaction with human monoclonal antibodies. Mol Immunol. 2011; 49:56-63. doi: 10.1016/j.molimm.2011.07.024 PMID: 21899894
25. Pierangeli SS, Liu X, Espinola R, Olee T, Zhu M, Harris NE, et al. Functional analyses of patient-derived IgG monoclonal anticardiolipin antibodies using in vivo thrombosis and in vivo microcirculation models. Thromb Haemost. 2000; 84:388-95. PMID: 11019960
26. Giles I, Pericleous C, Liu X, Ehsanullah J, Clarke L, Brogan P, et al. Thrombin binding predicts the effects of sequence changes in a human monoclonal antiphospholipid antibody on its in vivo biologic actions. J Immunol. 2009; 182:4836-43. doi: 10.4049/jimmunol.0804241 PMID: 19342662
27. Ioannou Y, Romay-Penabad Z, Pericleous C, Giles I, Papalardo E, Vargas G, et al. In vivo inhibition of antiphospholipid antibody-induced pathogenicity utilizing the antigenic target peptide domain I of beta2-glycoprotein I: proof of concept. J Thromb Haemost. 2009; 7:833-42. doi: 10.1111/j.1538-7836. 2009.03316.x PMID: 19220729
28. Agostinis C, Durigutto P, Sblattero D, Borghi MO, Grossi C, Guida F, et al. A non-complement-fixing antibody to beta2 glycoprotein I as a novel therapy for antiphospholipid syndrome. Blood. 2014; 123:3478-87. doi: 10.1182/blood-2013-11-537704 PMID: 24642748
29. de Laat B, van Berkel M, Urbanus RT, Siregar B, de Groot PG, Gebbink MF, et al. Immune responses against domain I of beta(2)-glycoprotein I are driven by conformational changes: domain I of beta(2)-glycoprotein I harbors a cryptic immunogenic epitope. Arthritis Rheum. 2011; 63:3960-8. doi: 10.1002/ art.30633 PMID: 21898342
30. Akhter E, Shums Z, Norman GL, Binder W, Fang H, Petri M. Utility of antiphosphatidylserine/prothrombin and IgA antiphospholipid assays in systemic lupus erythematosus. J Rheumatol. 2013; 40:282-6. doi: 10.3899/jrheum.120084 PMID: 23378459
31. Sweiss NJ, Bo R, Kapadia R, Manst D, Mahmood F, Adhikari T, et al. IgA anti-beta2-glycoprotein I autoantibodies are associated with an increased risk of thromboembolic events in patients with systemic lupus erythematosus. PLoS One. 2010; 5:e12280. doi: 10.1371/journal.pone.0012280 PMID: 20808864
32. Iverson GM, von Muhlen CA, Staub HL, Lassen AJ, Binder W, Norman GL. Patients with atherosclerotic syndrome, negative in anti-cardiolipin assays, make IgA autoantibodies that preferentially target domain 4 of beta2-GPI. J Autoimmun. 2006; 27:266-71. PMID: 17081732
33. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982; 25:1271-7. PMID: 7138600
34. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997; 40:1725.
35. Craig R, Mindell J. Health Survey for England-2006, CVD and risk factors for adults, obesity and risk factors for children. In: Centre HaSCI, editor. Leeds, UK2008.
36. Pierangeli SS, Harris EN. A protocol for determination of anticardiolipin antibodies by ELISA. Nat Protoc. 2008; 3:840-8. doi: 10.1038/nprot.2008.48 PMID: 18451792
37. Giles I, Haley J, Nagl S, Latchman D, Chen P, Chukwuocha R, et al. Relative importance of different human aPL derived heavy and light chains in the binding of aPL to cardiolipin. Mol Immunol. 2003; 40:49-60. PMID: 12909130
38. Ioannou Y, Giles I, Lambrianides A, Richardson C, Pearl LH, Latchman DS, et al. A novel expression system of domain I of human beta2 glycoprotein I in Escherichia coli. BMC Biotechnol. 2006; 6:8-18. PMID: 16472380
39. Petri M. Epidemiology of the antiphospholipid antibody syndrome. J Autoimmun. 2000; 15:145-51. PMID: 10968901
40. Florkowski CM. Sensitivity, specificity, receiver-operating characteristic (ROC) curves and likelihood ratios: communicating the performance of diagnostic tests. Clin Biochem Rev. 2008; 29 Suppl 1:S83-7. PMID: 18852864
41. Bertolaccini ML, Amengual O, Andreoli L, Atsumi T, Chighizola CB, Forastiero R, et al. 14th International Congress on Antiphospholipid Antibodies Task Force. Report on antiphospholipid syndrome laboratory diagnostics and trends. Autoimmun Rev. 2014; 13:917-30. doi: 10.1016/j.autrev.2014.05.001 PMID: 24824074
42. Lakos G, Favaloro EJ, Harris EN, Meroni PL, Tincani A, Wong RC, et al. International consensus guidelines on anticardiolipin and anti-beta2-glycoprotein I testing: report from the 13th International Congress on Antiphospholipid Antibodies. Arthritis Rheum. 2012; 64:1-10. doi: 10.1002/art.33349 PMID: 21953634
43. Banzato A, Pozzi N, Frasson R, De Filippis V, Ruffatti A, Bison E, et al. Antibodies to Domain I of beta (2)Glycoprotein I are in close relation to patients risk categories in Antiphospholipid Syndrome (APS). Thromb Res. 2011; 128:583-6. doi: 10.1016/j.thromres.2011.04.021 PMID: 21620443
44. Mondejar R, Gonzalez-Rodriguez C, Toyos-Saenz de Miera FJ, Melguizo-Madrid E, Zohoury N, Mahler M, et al. Role of antiphospholipid score and anti-beta2-glycoprotein I Domain I autoantibodies in the diagnosis of antiphospholipid syndrome. Clin Chim Acta. 2014; 431C:174-8.
45. Pengo V, Ruffatti A, Tonello M, Cuffaro S, Banzato A, Bison E, et al. Antibodies to Domain 1 (Dm1) of beta2-Glycoprotein 1 (beta2GP1) correctly classify patients at risk in Antiphospholipid Syndrome (APS). J Thromb Haemost. 2015; 13:1-6.
46. Willis R, Mahler M, Pregnolato F, Pericleous C, Rahman A, Ioannou Y, et al. Clinical evaluation of two anti-beta2glycoprotein I domain 1 autoantibody assays to aid in the diagnosis and risk assessment of the antiphospholipid syndrome. Arthritis Rheum. 2013; 65:S3.
47. CousinsL. PericleousC. KhamashtaM. BertolacciniM.L. IoannouY. GilesI.et alAntibodies to domain I of beta-2-glycoprotein I and IgA antiphospholipid antibodies in patients with seronegativeantiphospholipid syndromeAnn Rheum Dis.201574317-31910.1136/annrheumdis-2014-206483PMID: 25359383